(Q36643866)

15 August 2017

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (English)

1 reference

multicenter clinical trial

15 August 2017

0 references

1 reference

J M W van Haarst

1

1 reference

15 August 2017

P Baas

2

1 reference

15 August 2017

Ch Manegold

3

1 reference

15 August 2017

J H Schouwink

4

1 reference

15 August 2017

J A Burgers

5

1 reference

15 August 2017

H G de Bruin

6

1 reference

15 August 2017

W J Mooi

7

1 reference

15 August 2017

R J van Klaveren

8

1 reference

15 August 2017

M J A de Jonge

9

1 reference

15 August 2017

J P van Meerbeeck

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

86

1 reference

15 August 2017

3

1 reference

15 August 2017

342-345

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

15 August 2017

start time

1 February 2002

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600118

0 references

cites work

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Chemotherapy in malignant pleural mesothelioma. A review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Interaction between cisplatin and gemcitabine in vitro and in vivo.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Optimal two-stage designs for phase II clinical trials

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375227

Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

20 September 2018

1 reference

12 December 2020

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

12 December 2020

Malignant pleural mesothelioma

1 reference

12 December 2020

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Nonparametric Estimation from Incomplete Observations

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600118

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6600118

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

11875695

1 reference